Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled molgramostim versus placebo in autoimmune pulmonary alveolar proteinosis
NL-OMON46238Phase 2Active, not recruiting
- Sponsor
- Savara
- Start
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Savara. Primary endpoint: Oxygen uptake after inhaled molgramostim compared to placebo after 24 weeks of treatment. Started Mar 2016; status: active, not recruiting.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NL-OMON46238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46238.